SEARCH BY

Issuer directory Issuer directory
KEYWORDS
COMPANIES / ISIN
TYPE OF INFORMATION
INDUSTRY

Start search  ADVANCED SEARCH

COMPARTMENTS / INDICES

France
America
Asia
Oceania
Africa
Europe

MSI NEWS

FEEDS

My RSS My Google Microsoft Live My Yahoo

INDEX SEARCH RESULT

2020.09.18 | 15:20 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer - HTML (w)

2020.09.18 | 07:03 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce Roche launches new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines - HTML (w)

2020.09.18 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce Roche’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia - HTML (w)

2020.09.18 | 05:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

VIFOR PHARMA

puce Vifor Pharma Group Announces Successful Sale of OM Pharma - HTML (w)

2020.09.17 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020 - HTML (w)

2020.09.16 | 23:02 | Permanent Information Releases / General Company News

English version HTML (w) Mail

NOVARTIS

puce Novartis Tafinlar® + Mekinist® demonstrates long-term, relapse-free survival benefit for high-risk, stage III melanoma patients in study published in NEJM - HTML (w)

2020.09.16 | 16:24 | Permanent Information Releases / General Company News

English version HTML (w) Mail

NOVARTIS

puce Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond - HTML (w)

2020.09.16 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer - HTML (w)

2020.09.14 | 12:15 | Permanent Information Releases / General Company News

English version HTML (w) Mail

NOVARTIS

puce European Medicines Agency (EMA) approves safety label update for Novartis Beovu® - HTML (w)

2020.09.14 | 07:15 | Permanent Information Releases / General Company News

English version HTML (w) Mail

NESTLE

puce Nestlé commences tender offer for Aimmune Therapeutics, Inc. - HTML (w)

2020.09.14 | 07:15 | Permanent Information Releases / Sales and Revenues

English version HTML (w) Mail

NOVARTIS

puce Novartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME) - HTML (w)

2020.09.11 | 17:05 | Permanent Information Releases / General Company News

English version HTML (w) Mail

NOVARTIS

puce Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS) - HTML (w)

2020.09.11 | 17:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

NOVARTIS

puce Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis - HTML (w)

2020.09.11 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce New data further reinforce Roche’s OCREVUS (ocrelizumab) as a highly effective treatment for people with multiple sclerosis - HTML (w)

2020.09.10 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce New data show Roche’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD) - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 1000